SARPOGRELATE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H31NO6
Molecular Weight	429.506
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1

InChI

InChIKey=FFYNAVGJSYHHFO-UHFFFAOYSA-N

InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)

HIDE SMILES / InChI

Molecular Formula	C24H31NO6
Molecular Weight	429.506
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17438407
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/sarpogrelate.html | https://www.ncbi.nlm.nih.gov/pubmed/10980267 | https://clinicaltrials.gov/ct2/show/NCT01165567 | http://www.e-search.ne.jp/~jpr/PDF/MT02.PDF

Sarpogrelate (brand name Anplag; former developmental code names MCI-9042, LS-187,118) is a drug which acts as an antagonist at the 5HT2A and 5-HT2B receptors. It blocks serotonin-induced platelet aggregation and has applications in the treatment of many diseases including diabetes mellitus, Buerger's disease, Raynaud's disease, coronary artery disease, angina pectoris, and atherosclerosis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 2a (5-HT2a) receptor 237 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8937629	Agonist 2752		8.38 nM [Ki]
Serotonin 2b (5-HT2b) receptor 60 Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17609583	Agonist 2752		6.11 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic arterial occlusion 5 Sources: http://www.e-search.ne.jp/~jpr/PDF/MT02.PDF	Primary		Approved 8583	Anplag Approved Use INDICATIONS. Improvement of ischemic symptoms including ulcer, pain and feeling of coldness, associated with chronic arterial occlusion
Contrast induced nephropathy 2 Sources: https://clinicaltrials.gov/ct2/show/NCT01165567	Preventing		Phase IV 63	Anplag Approved Use INDICATIONS. Improvement of ischemic symptoms including ulcer, pain and feeling of coldness, associated with chronic arterial occlusion

C_max

Value	Dose	Analyte	Population
0.3636 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.7218 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
565 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
506.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
62.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
49.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
721.4 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
467.3 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
761 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
0.2908 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.5958 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1754 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1358.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
361 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
291.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2352.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1927.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1772.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
0.753 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.753 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Analyte	Population
5% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=25	SARPOGRELATE serum	Homo sapiens
96.8% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24167220/	SARPOGRELATE plasma	Homo sapiens
72% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24167220/	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens

Doses

Dose	Population	Adverse events
200 mg 3 times / day multiple, oral Higher than recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/	Other AEs: Elevated liver enzymes, Upper gastrointestinal symptoms... Other AEs: Elevated liver enzymes (3.3%) Upper gastrointestinal symptoms (0.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/

AEs

AE	Significance	Dose	Population
Upper gastrointestinal symptoms	0.8%	200 mg 3 times / day multiple, oral Higher than recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/
Elevated liver enzymes	3.3%	200 mg 3 times / day multiple, oral Higher than recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 879 CYP2C8 1057 CYP2E1 1060 CYP1A2 2153 CYP2B6 926 CYP2C19 2057 P-gp 1741 CYP3A5 136 BCRP 910	P-gp 2052 UGT1A4 399 UGT2B4 278 UGT1A9 423 UGT2B7 456

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2B6 1160	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP2B6 1160	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP3A5 201	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27695293/	no [Inhibition 10 uM]
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27695293/	no [Inhibition 10 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27695293/	no [Inhibition 10 uM]
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27695293/	no [Inhibition 10 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5160#section=Biological-Test-Results Page: 54.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5160#section=Biological-Test-Results \| https://pubmed.ncbi.nlm.nih.gov/25268386/ Page: 1.0	yes [IC50 0.195 uM]		yes (co-administration study) Comment: Co-administration increased Metoprolol AUCt by 1.53-fold and Cmax by 1.62-fold Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5160#section=Biological-Test-Results \| https://pubmed.ncbi.nlm.nih.gov/25268386/ Page: 1.0
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	yes [IC50 0.201 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5160#section=Biological-Test-Results Page: 6.0	yes [IC50 19.4971 uM]

Drug as victim

Target	Modality	Activity	Metabolite
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23704698/	minor [Km 96.3 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5160#section=Biological-Test-Results Page: 34.0	no
UGT2B4 278	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23704698/	yes [Km 186.6 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23704698/	yes [Km 476.2 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23704698/	yes [Km 564.1 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2

PubMed

Title	Date	PubMed
Serotonin potentiates angiotensin II--induced vascular smooth muscle cell proliferation.	2001 Dec	11730806
Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time.	2001 Dec 21	11755147
Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans.	2001 Jul	11505083
Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation.	2001 Jul-Aug	11455205
Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency.	2001 Jun	11426759
Assessment of affinity and dissociation ability of a newly synthesized 5-HT2 antagonist, AT-1015: comparison with other 5-HT2 antagonists.	2001 Nov	11885967
Binding affinity of a newly synthesized 5-HT2 antagonist, AT-1015 (N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-piperidino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate), in the rabbit platelet membrane.	2001 Oct	11642330
Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart.	2001 Sep	11599776
[Involvement of peripheral 5-HT2A receptor activation in inflammatory pain].	2001 Sep	11554035
AT-1015, a newly synthesized 5-HT2 receptor antagonist, dissociates slowly from the 5-HT2 receptor sites in rabbit cerebral cortex membrane.	2002 Aug	12195828
Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris.	2002 Aug	12177659
Effects of chronic administration of sarpogrelate on systolic blood pressure of spontaneously hypertensive rats: comparison with quinapril.	2002 Feb	11803246
Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries.	2002 Feb 1	11834523
DOI, a 5-HT2 receptor agonist, induces renal vasodilation via nitric oxide in anesthetized dogs.	2002 Feb 15	11864643
Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats.	2002 Jan	12000979
[Pharmacological analysis of inhibitory effect of sarpogrelate hydrochloride on human radial artery contraction].	2002 Jan	11868372
Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease.	2002 Jan	11808836
Changed responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: possible role of 5-hydroxytryptamine for diabetic bladder dysfunction.	2002 Jul	12050561
Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes.	2002 May	11937776
Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.	2003 Dec 1	14659815
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.	2003 May	12732383
The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation.	2003 May	12720492
Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.	2003 May 30	12738034
Effects of R-102444, an orally active 5-HT2A receptor antagonist, in rat models of peripheral vascular disease.	2004 Feb	15135326
Sarpogrelate: cardiovascular and renal clinical potential.	2004 Jul	15212624
New treatment of lumbar disc herniation involving 5-hydroxytryptamine2A receptor inhibitor: a randomized controlled trial.	2005 Apr	15871484
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.	2005 Sep	16093733
Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study.	2006 May	16886837
Livedo racemosa as a cutaneous manifestation of polycythemia vera.	2006 May-Jun	16709504
Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease.	2006 Nov	17062970
5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury.	2006 Sep 27	16876202
Sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, attenuates neurogenic pain induced by nucleus pulposus in rats.	2007 Feb 1	17268262
Identification of a key amino acid of the human 5-HT(2B) serotonin receptor important for sarpogrelate binding.	2007 Jul	17609583
Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.	2008 Apr	18175064
Both 5-hydroxytryptamine 5-HT2A and 5-HT1B receptors are involved in the vasoconstrictor response to 5-HT in the human isolated internal thoracic artery.	2008 Jul	18430065
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.	2008 Mar	18235151
Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS.	2009 Aug	19520981
Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts.	2009 Sep	19700096
Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia.	2010 Jan	19834330

Patents

Sample Use Guides

In Vivo Use Guide

The usual dosage for adult patients is 100 mg of sarpogrelate hydrochloride, administered after meal three times a day. The dosage may be adjusted according to the patient’s age and symptoms.

Route of Administration: Oral

In Vitro Use Guide

Stably expressing cell lines were constructed in HEK293 cells by transfecting with Lipofectamine 2000 reagent and selecting with 0.5 mg/ml G418-containing growth medium. Cells were split into 24-well plates at a density of 105 cells /well and labeled with 3 μCi/ml [3H]myo-inositol in serum-free DMEM for 24 h. Then the cells were washed with the assay medium (20 mM LiCl, 130 mM NaCl, 900 μM NaH2PO4, 5.4 mM KCl, 1.8 mM CaCl2, and 25 mM glucose in 20 mM HEPES, pH 7.4) and incubated with both SARPOGRELATE (10−9 – 10−4 M) at 37°C for 1 h. Cell extracts, in 10 mM formic acid, were applied to a 1-ml AG1-X8 resin (100 – 200 mesh; Assist Co., Tokyo) column before elution by buffer containing 1 M ammonium formate and 0.1 M formic acid. Radioactivity was measured by a liquid scintillation spectrophotometer.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:16:38 GMT 2025` Edited by `admin` on `Mon Mar 31 18:16:38 GMT 2025`
Record UNII	19P708E787
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

4-(1-(2-(3-METHOXYPHENETHYL)PHENOXY)-3-(DIMETHYLAMINO)PROPAN-2-YLOXY)-4-OXOBUTANOIC ACID SARPOGRELATE

Preferred Name

English

SARPOGRELATE

Official Name

English

Sarpogrelate [WHO-DD]

Common Name

English

BUTANEDIOIC ACID, 1-(2-(DIMETHYLAMINO)-1-((2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)METHYL)ETHYL) ESTER

Systematic Name

English

BUTANEDIOIC ACID, MONO(2-(DIMETHYLAMINO)-1-((2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)METHYL)ETHYL) ESTER

Common Name

English

sarpogrelate [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1327